keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma stage system

keyword
https://www.readbyqxmd.com/read/28323121/the-treatment-of-intermediate-stage-tumour-beyond-tace-from-surgery-to-systemic-therapy
#1
REVIEW
Peter R Galle, Francesco Tovoli, Friedrich Foerster, Marcus A Wörns, Alessandro Cucchetti, Luigi Bolondi
Intermediate stage hepatocellular carcinoma (HCC) comprises the largest subgroup of patients with this disease and is characterized by substantial heterogeneity. Functional liver impairment, total tumour burden and other prognostic factors such as high alpha-fetoprotein serum level, presence of micro-vascular invasion, and poorly differentiated tumours relevantly contribute to outcome. The usage of the standard therapeutic approach, transarterial chemoembolization - TACE, for all intermediate stage HCC patients is probably an over-simplification and may therefore not be appropriate for all patients...
March 17, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28301998/prognostic-factors-and-staging-systems-in-hepatocellular-carcinoma
#2
Haldun Selçuk
There are a number of factors that should be taken into consideration when predicting the outcomes and prognosis of hepatocellular carcinoma. Four of the most important factors in determining survival are the severity of the accompanying liver disease, tumor size and number, extension of the tumor into other structures, and presence of metastases. The most common and widely accepted tumor staging systems include these 4 prognostic factors. The staging systems are (1) the tumor-node-metastasis system of the American Joint Committee on cancer, (2) the Okuda system, (3) the Barcelona Clinic Liver Cancer system, (4) the Cancer of the Liver Italian Program score; (5) the recent albumin-bilirubin grading system, and finally (6) the Hong Kong Liver Cancer staging system...
March 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28299645/new-concepts-in-embolotherapy-of-hcc
#3
REVIEW
F Pesapane, N Nezami, F Patella, J F Geschwind
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide with rapidly growing incidence rates in the USA and Europe. Despite improving surveillance programs, most patients are diagnosed at intermediate to advanced stages and are no longer amenable to curative therapies, such as ablation, surgical resection and liver transplantation. For such patients, catheter-based image-guided embolotherapies such as transarterial chemoembolization (TACE) represent the standard of care and mainstay therapy, as recommended and endorsed by a variety of national guidelines and staging systems...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28296727/prognostic-nomogram-for-patients-with-hepatocellular-carcinoma-underwent-adjuvant-transarterial-chemoembolization-following-curative-resection
#4
Chu-Yu Jing, Yi-Peng Fu, Su-Su Zheng, Yong Yi, Hu-Jia Shen, Jin-Long Huang, Xin Xu, Jia-Jia Lin, Jian Zhou, Jia Fan, Zheng-Gang Ren, Shuang-Jian Qiu, Bo-Heng Zhang
Adjuvant transarterial chemoembolization (TACE) is a major option for postoperative hepatocellular carcinoma (HCC) patients with recurrence risk factors. However, individualized predictive models for subgroup of these patients are limited. This study aimed to develop a prognostic nomogram for patients with HCC underwent adjuvant TACE following curative resection.A cohort comprising 144 HCC patients who received adjuvant TACE following curative resection in the Zhongshan Hospital were analyzed. The nomogram was formulated based on independent prognostic indicators for overall survival (OS)...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28292478/real-world-data-for-the-evaluation-of-transarterial-radioembolization-versus-sorafenib-in-hepatocellular-carcinoma-a-cost-effectiveness-analysis
#5
Carla Rognoni, Oriana Ciani, Silvia Sommariva, Rosanna Tarricone
OBJECTIVES: To perform a cost-effectiveness analysis comparing the use of transarterial radioembolization (TARE) with that of sorafenib in the treatment of patients with intermediate or advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system. METHODS: Patient-level data were consecutively recorded and collected at three oncology centers in Italy. A propensity score matching was performed to compare patients with similar clinical characteristics who underwent TARE or sorafenib treatment...
March 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28281295/management-of-people-with-intermediate-stage-hepatocellular-carcinoma-an-attempted-network-meta-analysis
#6
REVIEW
Davide Roccarina, Avik Majumdar, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy
BACKGROUND: There is significant uncertainty in the treatment of intermediate-stage hepatocellular carcinoma which is defined by the Barcelona Clinic Liver Cancer (BCLC) as hepatocellular carcinoma stage B with large, multi-nodular, Child-Pugh status A to B, performance status 0 to 2, and without vascular occlusion or extrahepatic disease. OBJECTIVES: To assess the comparative benefits and harms of different interventions used in the treatment of intermediate-stage hepatocellular carcinoma (BCLC stage B) through a network meta-analysis and to generate rankings of the available interventions according to their safety and efficacy...
March 10, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28266600/percutaneous-irreversible-electroporation-long-term-survival-analysis-of-71-patients-with-inoperable-malignant-hepatic-tumors
#7
C Niessen, S Thumann, L Beyer, B Pregler, J Kramer, S Lang, A Teufel, E M Jung, C Stroszczynski, P Wiggermann
Aim of this retrospective analysis was to evaluate the survival times after percutaneous irreversible electroporation (IRE) in inoperable liver tumors not amenable to thermal ablation. 71 patients (14 females, 57 males, median age 63.5 ± 10.8 years) with 103 liver tumors were treated in 83 interventions using IRE (NanoKnife(®) system). The median tumor short-axis diameter was 1.9 cm (minimum 0.4 cm, maximum 4.5 cm). 35 patients had primary liver tumors and 36 patients had liver metastases. The Kaplan-Meier method was employed to calculate the survival rates, and the different groups were compared using multivariate log-rank and Wilcoxon tests...
March 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28261594/hepatocellular-carcinoma-with-macrovascular-invasion-treated-with-yttrium-90-radioembolization-prior-to-transplantation
#8
Giovanni Battista Levi Sandri, Giuseppe Maria Ettorre, Marco Colasanti, Edoardo De Werra, Gianluca Mascianà, Daniele Ferraro, Giovanni Tortorelli, Rosa Sciuto, Pierleone Lucatelli, Giuseppe Pizzi, Ubaldo Visco-Comandini, Giovanni Vennarecci
BACKGROUND: Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure. METHODS: From January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center...
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28261593/staging-of-intrahepatic-cholangiocarcinoma
#9
REVIEW
Sean M Ronnekleiv-Kelly, Timothy M Pawlik
Intrahepatic cholangiocarcinoma (ICC) comprises approximately 5-30% of primary liver tumors, however it has been increasing over the last several decades. Up to and including the 6(th) edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) edition staging system, ICC was staged the same as hepatocellular carcinoma. In the 7(th) edition AJCC/UICC manual, the staging system of ICC was revised such that a distinct classification was proposed. Pathologic features for prognosis included vascular invasion, tumor multiplicity, local extension, periductal infiltration and lymph nodal metastasis...
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28260649/higher-serum-interleukin-17a-levels-as-a-potential-biomarker-for-predicting-early-disease-progression-in-patients-with-hepatitis-b-virus-associated-advanced-hepatocellular-carcinoma-treated-with-sorafenib
#10
Hyo Jung Cho, Soon Sun Kim, Ji Sun Nam, Min Jung Oh, Dae Ryong Kang, Jai Keun Kim, Jei Hee Lee, Bohyun Kim, Min Jae Yang, Jae Chul Hwang, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Sung Won Cho, Jae Youn Cheong
BACKGROUND: Although sorafenib is the only available drug with proven efficacy for patients with advanced hepatocellular carcinoma (HCC), the clinical efficacy of sorafenib is variable and unpredictable. The aim of the current study was to identify potential serum biomarkers predicting cancer progression and overall survival (OS) in patients with hepatitis B virus (HBV)-related advanced HCC treated with sorafenib. METHODS: Thirty-four patients with HBV-related advanced HCC (modified Union for International Cancer Control [UICC] stage IVa or IVb) treated with sorafenib for more than 4weeks were retrospectively enrolled...
March 2, 2017: Cytokine
https://www.readbyqxmd.com/read/28258743/loco-regional-treatment-of-hcc-current-status
#11
REVIEW
L Crocetti, I Bargellini, R Cioni
Hepatocellular carcinoma (HCC) represents one of the few cancers for which locoregional treatments are recognised as being able to cure and/or prolong survival and are included in international guidelines. This is due to the unique nature of HCC, in most cases occurring in patients with underlying virus- or alcohol-related cirrhosis. The treatment choice in patients with HCC is therefore driven not only by tumour staging, as in the great majority of cancers, but also by careful evaluation of liver function and physical status...
February 28, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28250317/strategic-drug-design-to-avoid-the-metabolic-activation-of-hepatotoxic-drugs
#12
Tomoyuki Ohe, Kyoko Takahashi, Shigeo Nakamura, Tadahiko Mashino
 Adverse reactions are one of the most important issues in drug development, as well as in the therapeutic usage of drugs during the post-approval stage. Specifically, idiosyncratic adverse drug reactions (IDR) occur in only a small group of patients who are treated with certain drugs, and are unpredictable. It is widely accepted that drug-induced IDR is often associated with CYP-mediated bioactivation. Benzbromarone (BBR) is effective in the treatment of hyperuricemia, and has been used as an effective drug in Japan for a long time...
2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/28213044/hepatocellular-carcinoma-screening-associated-with-early-tumor-detection-and-improved-survival-among-patients-with-cirrhosis-in-the-united-states
#13
Amit G Singal, Sahil Mittal, Olutola A Yerokun, Chul Ahn, Jorge Marrero, Adam Yopp, Neehar D Parikh, Steve J Scaglione
BACKGROUND: Professional societies recommend hepatocellular carcinoma screening in patients with cirrhosis but high-quality data evaluating its effectiveness to improve early tumor detection and survival in "real world" clinical practice are needed. AIMS: Characterize the association between hepatocellular carcinoma screening and early tumor detection, curative treatment, and overall survival among patients with cirrhosis. METHODS: We performed a retrospective cohort study of patients diagnosed with hepatocellular carcinoma between June 2012 and May 2013 at four health systems in the United States...
February 14, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28195873/niace-score-for-hepatocellular-carcinoma-patients-treated-by-surgery-or-transarterial-chemoembolization
#14
Xavier Adhoute, Guillaume Pénaranda, Jean Luc Raoul, Emilie Bollon, Bernard Pol, Yves P Letreut, Hervé Perrier, Olivier Bayle, Olivier Monnet, Patrick Beaurain, Cyril Muller, Jean Hardwigsen, Gaëlle Lefolgoc, Paul Castellani, Jean P Bronowicki, Marc Bourlière
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) prognostic scores could be useful in addition to the Barcelona Clinic Liver Cancer (BCLC) system to clarify patient prognosis and guide treatment decision. The NIACE (tumor Nodularity, Infiltrative nature of the tumor, serum Alpha-fetoprotein level, Child-Pugh stage, ECOG performance status) score distinguishes different prognosis groups among BCLC A, B, and C HCC patients. Our aims are to evaluate the NIACE score and its additive value in two HCC cohorts treated either by surgery or by chemoembolization, and then according to the BCLC recommendations...
February 13, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28186970/high-expression-of-gfat1-predicts-unfavorable-prognosis-in-patients-with-hepatocellular-carcinoma
#15
Lili Li, Miaomiao Shao, Peike Peng, Caiting Yang, Shushu Song, Fangfang Duan, Dongwei Jia, Mingming Zhang, Junjie Zhao, Ran Zhao, Weicheng Wu, Lan Wang, Can Li, Hao Wu, Jie Zhang, Xin Wu, Yuanyuan Ruan, Jianxin Gu
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. As a branch of glucose metabolism, hexosamine biosynthesis pathway (HBP) has been reported to play a critical role in the insulin resistance and progression of cancer. Glutamine:fructose-6-phosphate amidotransferase (GFAT) is the rate-limiting enzyme of the HBP; nevertheless, the prognostic value of GFAT1 in HCC remains elusive. In this study, we found that high expression of GFAT1 was significantly associated with serum alpha-fetoprotein (AFP), serum alanine aminotransferase (ALT), tumor size, tumor encapsulation, T stage and TNM stage...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28185302/patterns-and-challenges-of-treatment-sequencing-in-patients-with-hepatocellular-carcinoma-experience-from-a-referral-center
#16
Martha M Kirstein, Nora Schweitzer, Theresa Winter, Katerina Lappas, Nathalie Graen, Isabell Kunstmann, Torsten Voigtländer, Tanja Reineke-Plaaß, Michael P Manns, Frank Lehner, Thomas Rodt, Arndt Vogel
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers. Several local and systemic therapies are available for patients with HCC depending on the stage of the disease. In clinical practice, treatment decision-making and sequencing may be very heterogeneous. METHODS: In this study, we retrospectively analyzed treatment algorithms in 2,101 patients with HCC treated from 2000 to 2015 at Hannover Medical School, Germany. RESULTS: Transarterial chemoembolization (TACE) was the most common initial treatment (n = 545; 25...
February 10, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28170405/treatment-algorithm-based-on-the-multivariate-survival-analyses-in-patients-with-advanced-hepatocellular-carcinoma-treated-with-trans-arterial-chemoembolization
#17
Hasmukh J Prajapati, Hyun S Kim
PURPOSE: To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE). METHODS: Consecutive unresectable and non-tranplantable patients with advanced HCC, who received DEB TACE were studied. A total of 238 patients (mean age, 62.4yrs) was included in the study. Survivals were analyzed according to different parameters from the time of the 1st DEB TACE...
2017: PloS One
https://www.readbyqxmd.com/read/28169483/the-prognostic-significance-of-albi-albumin-bilirubin-t-score-in-patient-who-underwent-hepatic-resection-for-hepatocellular-carcinoma
#18
Norifumi Harimoto, Tomoharu Yoshizumi, Kazuhito Sakata, Akihisa Nagatsu, Takashi Motomura, Shinji Itoh, Noboru Harada, Toru Ikegami, Hideaki Uchiyama, Yuji Soejima, Yoshihiko Maehara
BACKGROUND: In recent years, the establishment of new staging systems for hepatocellular carcinoma (HCC) has been reported worldwide. Albumin-bilirubin (ALBI) with TNM stage of Liver Cancer Study Group of Japan was called as ALBI-T score. STUDY DESIGN: Patient data were retrospectively collected for 357 consecutive patients who had undergone hepatic resection for HCC with curative intent between January 2004 and December 2015. The overall survival and recurrence-free survival were compared by the Kaplan-Meier method, by different staging system: the Japan integrated staging (JIS), modified JIS and ALBI-T...
February 7, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28160422/survival-benefit-of-hepatic-resection-for-hepatocellular-carcinoma-beyond-the-barcelona-clinic-liver-cancer-classification
#19
Kenei Furukawa, Hiroaki Shiba, Takashi Horiuchi, Yoshihiro Shirai, Koichiro Haruki, Yuki Fujiwara, Taro Sakamoto, Takeshi Gocho, Katsuhiko Yanaga
BACKGROUND: The Barcelona Clinic Liver Cancer (BCLC) classification is the most widely used staging system for hepatocellular carcinoma (HCC), but its prognostic ability in patients after resection has not been yet validated. The aim of this study was to evaluate the BCLC classification among patients after resection. METHODS: The subjects were 196 patients who underwent hepatic resection for HCC between April 2003 and December 2014 at Jikei University Hospital...
February 3, 2017: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/28160206/distribution-of-tumor-stage-and-initial-treatment-modality-in-patients-with-primary-hepatocellular-carcinoma
#20
X Xiang, J-H Zhong, Y-Y Wang, X-M You, L Ma, B-D Xiang, L-Q Li
OBJECTIVE: This study reviewed the distribution of each tumor stage and each type of initial treatment modality among patients with primary hepatocellular carcinoma (HCC) treated at a tertiary tumor hospital between January 2003 and October 2013. METHODS: Baseline data of patients with primary hepatocellular carcinoma treated between January 2003 and October 2013 were retrospectively collected. Tumor stage was determined according to the Barcelona Clinic Liver Cancer (BCLC) staging system and Hong Kong Clinic Liver Cancer (HKLC) staging system...
February 3, 2017: Clinical & Translational Oncology
keyword
keyword
66281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"